T he cancer stem cell theory proposes that tumors originate from stem cells that are capable of self-renewal while giving off rapidly replicating progeny that comprise the tumor bulk (1) . A small tumor-initiating subpopulation of cells, indicative of stem cells, has been identified for several human epithelial cancers (2) (3) (4) (5) (6) . Cells with stem-like properties also have been found in human tumor xenograft models and in many human cancer cell lines (7, 8) . With regard to the normal human breast, stem cells are proposed to be contained in a cell fraction that expresses epithelial-specific antigen (ESA) ϩ and ␣6 integrin (CD49f) ϩ . Additional putative stem cell markers include Musashi, the Polycomb group repressor Bmi-1, cytokeratins 5/6 (CK5/6), and label-retention and side-population cells (reviewed in ref. 9 ). Currently, tumorigenic cells from primary human breast cancers have been identified solely by CD44 ϩ CD24
Ϫ/low ESA ϩ expression (2) . Approximately 80% of breast cancers fall into luminal subtypes, which are estrogen receptor (ER) and progesterone receptor (PR)-positive and express cytokeratin 18 (CK18) (ER ϩ PR ϩ CK18 ϩ ). These tumors have a better prognosis and more varied treatment options, including endocrine therapies, than their basal ER Ϫ PR Ϫ CK5 ϩ counterparts. Nonetheless, hormone resistance and consequent tumor recurrence remain a problem for ER ϩ PR ϩ disease. The origin of luminal ER ϩ PR ϩ CK18 ϩ and basal ER Ϫ PR Ϫ CK5 ϩ breast cancers remains under debate. The cancer stem cell theory proposes that ER ϩ PR ϩ and ER Ϫ PR Ϫ breast cancers arise from normal breast epithelial stem cells, leading to debate about the steroid receptor content of these nontransformed stem cells. Studies based on normal mouse mammary gland models generally describe normal stem cells as being restricted to basal cell layers of the gland, which are ER Ϫ PR Ϫ (10) (11) (12) . However, ER ϩ PR ϩ label-retaining cells have also been described in the luminal epithelium of the mouse mammary gland (13, 14) . In the human breast, labelretaining and side-population cells are reportedly enriched for ER expression (15) . There is some speculation that ER Ϫ PR Ϫ basal epithelial stem cells spawn ER ϩ PR ϩ progenitor cells found in the luminal layer, which might also become tumorigenic (16 Solid tumors generated from estrogen-treated ER ϩ PR ϩ T47D human breast cancer xenografts predominantly express the luminal markers CK8 and CK18. However, a small (1%) subpopulation of cells within these tumors express CK5, a marker of the basal receptor-negative subtype of breast cancers (19) . These CK5 ϩ cells lack the basal epithelial marker CK14 and the myoepithelial marker smooth muscle actin and increase severalfold in number when progestins are given during tumor growth (19) . To characterize these cells, CK5 ϩ and CK5 Ϫ cells were isolated from tumor xenografts grown in mice treated with estradiol alone or with estradiol plus the progestin medroxyprogesterone acetate (6␣-methyl-17␣-hydroxyprogesterone acetate, MPA), using laser-capture microdissection of frozen tumor sections immunost ained for CK5 [supporting infor mation (SI) Text]. Their gene ex pression profiles were then c ompared. This generated a list of genes that were significantly changed in the CK5 ϩ compared with the CK5 Ϫ cells, from both estrogen and estrogenplus progestin-treated tumors (Dat aset S1 and Dat aset S2).
A volcano plot generated in Partek identified genes that were coexpressed in CK5 ϩ cells, by their significance (P value) and their CK5 ϩ /CK5 Ϫ ratio (Fig. 1A) . The putative cancer stem cell marker CD44 was among several genes whose expression was up-regulated in CK5 ϩ compared with CK5 Ϫ cells regardless of hormone treatments (Fig. 1B) . Dual CK5/CD44 immunohistochemistry on tumor sections confirmed that CD44 (red) is coexpressed with CK5 ϩ (green) in both estrogen and estrogenplus progestin-treated tumors (Fig. 1C) . Additionally, tumors treated with progestins had occasional CK5 ϩ cells that were CD44 Ϫ/low (arrow). This suggests that progestins increase a CK5 ϩ CD44 Ϫ subpopulation independent of the CK5 ϩ CD44 ϩ population. Dual immunohistochemistry for CK5/PR was performed on sections of estrogen and estrogen-plus progestin-treated tumors (Fig. 2) . Rare CK5 ϩ cells (green) in estrogen-treated tumors were typically (95%) PR Ϫ , whereas the surrounding tumor cells were PR ϩ (red nuclei). Although the vast majority of CK5 ϩ cells in estrogen-plus progestin-treated tumors were also PR Ϫ , a rare PR ϩ CK5 ϩ subpopulation was increased to Ϸ20% in progestintreated tumors (Fig. 2, ‫. )ء‬ Similarly, CK5 ϩ cells were mainly ER Ϫ , and an ER ϩ CK5 ϩ subpopulation was increased by estrogen-plus progestin treatment (Fig. S1 ).
The CD44 ؉ Cell Fraction from PR ؉ Tumors Produces Heterogeneous
Colonies Containing PR ؊ CK5 ؉ Cells in 3D Culture. We used the surface marker CD44 to isolate cells from solid T47D xenograft tumors, reasoning that the rare CK5 ϩ population would be contained within the CD44 ϩ fraction. T47D-ZsGreen cells were used for these experiments to help distinguish the human tumor cells from host mouse cells during FACS sorting (Fig. 3A) . Single-cell suspensions of tumor cells were depleted of Lin ϩ host cells, labeled with an Alexa Fluor 647 anti-CD44 antibody and CD44 ϩ cells (upper box), and CD44
Ϫ cells (lower box) were collected separately. The fraction of CD44 ϩ cells was consistently Ϸ1% in both estrogen and estrogen-plus progestin-treated solid tumors. A portion of sorted CD44 ϩ and CD44 Ϫ cells were spun onto slides, fixed, and stained for CD44 and CK5. Approximately 75% of the sorted CD44 ϩ cells and 2% of CD44 Ϫ cells were CK5 ϩ by immunostain (Fig. S2) . Flow cytometry also determined that Ϸ67% of unsorted CD44 ϩ cells were CK5
Sorted CD44 ϩ and CD44 Ϫ cells were plated into separate Matrigel-coated eight-well chambers at dilutions between 2 and 4 ϫ 10 3 in MEM supplemented with 5% FCS. After Ϸ3 weeks, large colonies reaching 200-500 m in diameter were observed in the CD44 ϩ population (Fig. 3B) . Rare surviving cells in the CD44 Ϫ population formed colonies Ͻ50 m in diameter. When the number of CD44
Ϫ cells was increased to Ͼ10 4 cells, colonies formed more often, presumably due to contaminating CD44 ϩ cells. Purity of flow sorts (postsort analysis) was determined to be Ϸ99%. Clonal analysis on soft agar determined that 1.7/10 3 CD44 Ϫ and 8.3/10 3 CD44 ϩ cells formed colonies. There was no difference in colony formation between CD44 ϩ cells isolated from estrogen or estrogen-plus progestin-treated tumors.
Serial sections of paraffin-embedded CD44 ϩ colonies were stained by immunohistochemistry for CD44, CD24, CK5, and PR (Fig. 3C) . Cells in the 3D colonies ubiquitously expressed CD44 and were mostly CD24 Ϫ/low , consistent with previously described tumorigenic breast cancer cells (2) . CD44 ϩ colonies contained rare peripherally located CK5 ϩ cells. The majority of cells in the colonies were PR ϩ . However, distinct PR Ϫ areas could be found in the vicinity of the rare CK5 ϩ cells. Because the CD44 Ϫ cells failed to grow significant colonies, we were unable to identify and stain them in paraffin sections.
Established CD44 ϩ 3D colonies were either untreated (control) or treated 24 h with MPA (ϩP). Dual immunohistochem- istry for CD44/PR and CK5/PR was performed on sections of CD44 ϩ colonies (Fig. 3 D and E) . Control colonies (Fig. 3D) were uniformly CD44 ϩ (green) but were heterogeneous for PR expression (red), containing both PR ϩ CD44 ϩ and PR Ϫ CD44 ϩ cells. The peripherally located CK5 ϩ cells (green) were PR Ϫ (red, lower center, arrows; and merged). Colonies were also heterogeneous for ER expression, and the peripheral CK5 ϩ cells were ER Ϫ (Fig. S4) . Like untreated colonies, progestin-treated colonies (Fig. 3E ) uniformly expressed CD44 (green) and were heterogeneous for PR (red). However, progestin-treated colonies contained an increased number of CK5 ϩ cells (green) compared with untreated colonies, with the additional appearance of rare PR ϩ CK5 ϩ cells (Fig. 3E, arrow) . Rare ER ϩ CK5 ϩ cells could also be seen in the progestin-treated colonies (Fig. S4) .
Prevalence of Nonexpanding PR ؊ CK5 ؉ Cells in Colony-Forming Units.
To determine the relationship between colony formation and PR Ϫ CK5 ϩ cells, we prepared single-cell suspensions from ER ϩ PR ϩ tumor xenografts and plated 10 4 cells directly onto six-well dishes with inserted glass coverslips in minimal media. Coverslips were removed, fixed, and stained for CK5/PR on days 3, 7, and 14. Select coverslips were treated with MPA for 24 h before fixation. Colony-forming units (three or more cells per colony at day 3, 20 or more at day 7, and 50 or more at day 14) were photographed, scored for CK5 and PR expression, and graphed as a function of positive cell number for each marker vs. colony size ( examples of bilateral dissected tumors at day 30 and tumors in intact mice at days 28 and 45. Tumor colonies were clearly visible in the CD44 ϩ set by 28 days after injection; they increased in size and coalesced with time. Much smaller CD44
Ϫ colonies tended to form late presumably due to contaminating CD44 ϩ cells. Overall, CD44 ϩ tumors were visible earlier and grew larger in 10/11 mice that received 10 3 to 10 5 cells (Table S1 ). (20) (21) (22) (23) .
The origin of these phenotypically diverse breast cancer subtypes has been explained by two competing theories. The clonal evolution theory proposes that diverse populations in tumors are the descendents of multiple transformed cells. The genetic diversity of subpopulations of breast cancer cells supports the postulate that heterogeneous cancer cells may have different origins (24) . Alternatively, the cancer stem cell theory proposes that only the long-lived stem cells of the normal breast have the capacity to accumulate oncogenic mutations. The identification of a small subpopulation of cells in several human cancers that have the unique ability to reconstitute a heterogeneous tumor in vivo supports this model (2) (3) (4) (5) (6) . Theoretically, in the cancer stem cell model, luminal breast cancers would arise from normal ER ϩ PR ϩ luminal stem/progenitor cells, whereas the basal subtypes would originate from normal ER Ϫ PR Ϫ stem cells in the basal cell layer. Stingl et al. (27) describe two types of progenitors in normal tissues of the human breast: luminalspecific progenitors and bipotent progenitors that generate both luminal and myoepithelial cells. These cells could potentially be oncogenic targets.
We describe a rare population of cells having a basal-like phenotype (ER Ϫ PR Ϫ CK5 ϩ ) that are contained within the CD44 ϩ fraction of luminal-like ER ϩ PR ϩ tumors. It has been proposed that CK5 ϩ cells in the normal human breast represent a stem/progenitor fraction that has the capacity to generate myoepithelial (SMA ϩ ) or luminal epithelial (CK8/18 ϩ ) lineages (25) . Analogously, CK5 ϩ basal stem cells of the prostate are proposed to populate both the AR Ϫ PSA Ϫ basal and AR ϩ PSA ϩ luminal epithelial cells (26) . In our hands, rare CK5 ϩ cells can be found in all ER ϩ PR ϩ human breast cancer cell lines, including T47D, MCF7, and ZR75 (data not shown). The stem-like CD44 ϩ CD24 Ϫ fraction of primary human breast cancers was recently described as ER Ϫ/low PR Ϫ/low and enriched for CK5 (24) . The CD44 ϩ fraction of our xenograft tumors cells was ESA ϩ and CD49f ϩ similar to previously described luminal-specific breast progenitor cells (ref. 27 ; Fig. S5 ). Within the CD44 ϩ population, the ER Ϫ PR Ϫ CK5 ϩ are likely to be colony initiators, because they are present at early colony formation (3-10 cells per colony), but their population is static and does not grow with colony expansion (Fig. 4A) .
The role of estrogens and progestins in breast epithelial stem cells or tumorigenic breast cancer cells is undefined. Progester- one is often considered to be a ''differentiating'' hormone in the breast, although there are data to suggest that it has proliferative actions as well (28) . Clinical studies indicate that progestin use in hormone replacement therapy is associated with increased breast cancer incidence (29) . The reasons for this are unclear. In our hands, progestin treatment of CD44 ϩ colonies in vitro and early tumors in vivo ''reactivates'' CK5 expression in a subpopulation of PR ϩ CK5 Ϫ , producing unusual PR ϩ CK5 ϩ cells. The extent of CK5 reactivation diminishes in larger colonies and tumors, suggesting that cells further removed from colony initiation have lost the capacity to express the CK5 marker. We postulate that the PR ϩ CK5 ϩ state is transitory between the PR Ϫ CK5 ϩ progenitors and more differentiated PR ϩ CK5 Ϫ cells. This is supported by PR/CK5 immunohistochemistry on normal human breast and ductal carcinomas. In both cases, CK5 and PR expression is mutually exclusive, although CK5 ϩ and PR ϩ cells are often found in close proximity (Fig. S6 and Fig. S7 ).
In summary, we postulate that the ER ϩ PR ϩ luminal breast cancer subtype contains a subpopulation of basal-like ER Ϫ PR Ϫ CK5 ϩ but luminal-specifying progenitor cells. If our model is correct, then in the case of ER ϩ PR ϩ breast cancers, endocrine therapies that target ER would be ineffective against the ER Ϫ PR Ϫ progenitor cells, providing an avenue for tumor recurrence.
Materials and Methods
Reagents. T47D cells stably expressing ZsGreen were described in ref. 30 . DMEM, MEM, and FBS were purchased from Life Technologies. Antibodies for immunohistochemistry included CK5 mAb (XM26, Novacastra), CD44 mAb (156 -3C11, Lab Vision), CD44 rabbit mAb (EPR1013Y, Epitomics), CD24 mAb (SN3b, Lab Vision), PR mAb (1294, Dako), PR rabbit mAb (SP2, Lab Vision), and CK18 rabbit mAB (AP1021, Calbiochem). Alexa Fluor 488-and 555-conjugated secondary antibodies were from Molecular Probes (In Vitrogen). An Alexa Fluor 647 conjugated CD44 antibody and matched isotype control (IgG2a) antibody (F10 -44-2, AbD Serotec) were used for FACS sorting.
Experimental Animals and Xenograft Tumor Growth. All animal procedures were performed under a protocol approved by the University of Colorado Institutional Animal Care and Use Committee. Ovariectomized nu/nu mice were purchased from Harlan Sprague-Dawley at 4 -6 weeks of age. The growth of T47D human breast cancer cells into solid tumors in these mice has been described in ref. 19 . For the current experiments, tumors were grown in the no. 4 mammary glands for 8 -10 weeks. Animals were supplemented with silastic implants containing estradiol only or estradiol plus the progestin MPA (19) .
Isolation and FACS Sorting of Tumor Cells.
Processing of xenograft tumors for cell sorting was performed by using a protocol adapted from Patrawala et al. (3) . Briefly, solid T47D-ZsGreen tumors were removed from mice and minced into small pieces in 2 ml of DMEM ϩ 5% FBS. Tumor pieces were collected by centrifugation at 150 ϫ g for 5 min, rinsed once in PBS, and digested in Accumax at 10 ml/g (Innovative Cell Technologies) for 30 min at 37°C, followed by 30 min at room temperature. Cells in the supernatant were collected and filtered through a 40-m nylon mesh (BD Biosciences). Lineage-positive (Lin ϩ ) host cells were depleted by using the mouse MACS Lineage Cell Depletion Kit (Miltenyi Biotech). The enriched human cancer cell suspension was blocked in phenol red free MEM plus 10% normal human serum (Innovative Research). Alexa Fluor 647-conjugated CD44 or the isotype control antibody were added directly to the cells for 30 min at room temperature. Cells were washed with 10ϫ volume MEM and sorted by using a MoFlo sorter based on viability (DAPI), green fluorescence (human cells), and red fluorescence (CD44 ϩ cells).
3D Matrigel Cultures and Colony Formation in Minimal
Media. Eight-well chambers (Lab-Tek Chamberslide) were loaded with 100 l of Growth Factor Reduced Matrigel (Becton-Dickinson) and allowed to set for 30 min. Sorted CD44 ϩ or CD44 Ϫ cells (2-4 ϫ 10 3 cells) were overlaid onto the gel in 200 l of MEM ϩ 5% FBS. Cultures were allowed to grow for 3-4 weeks, preserved with HistoGel (Richard-Allen Scientific), fixed in 4% paraformaldehyde, and embedded in paraffin. Vehicle (ethanol) or MPA (10 nM) was added to chambers 24 h before fixation. For assessment of early colony formation, unsorted single cell suspensions (10 4 cells) were plated in six-well plates (35-mm wells) containing glass coverslips in minimal media (MEGM) containing B27 supplement (InVitrogen), 20 g/ml each of EGF and FGF (Peprotech), and 4 g/ml heparin (Sigma). Cells were fixed and stained for CK5 and PR and counterstained with DAPI at days 3, 7, and 14. At each time point, vehicle or 10 nM MPA was added for 24 h before fixation. Colonies were identified under the DAPI filter as clusters of three or more cells at day 3, 20 or more cells at day 7, and 50 or more cells at day 14. Colonies were counted for total number of cells and for the number of CK5 ϩ , PR ϩ , and CK5 ϩ PR ϩ cells. GraphPad Prism (version 4.0) was used to plot data and perform linear regression analyses. Best-fit values for slope (m) and goodness of fit (r 2 ) are noted.
In Vivo Tumorigenesis Studies. Cells were isolated from T47D-ZsGreen human breast tumor xenografts grown for 8 -10 weeks in ovariectomized immature nude mice supplemented with estradiol, as described. For reimplantation studies, tumors were digested with collagenase IV/hyaluronidase type I-S (Sigma) and human epithelial tumor cells positively selected by using EpCAM microbeads (Miltenyi), followed by labeling with CD44 antibody and FACS. Sorted cells were collected by centrifugation, resuspended in 200 l of Matrigel, and injected into the no. 4 mammary glands. CD44 ϩ or CD44 Ϫ cells (10 3 , 10 4 , or 10 5 in different mice) were injected in opposite sides of the same mouse. Tumor growth was monitored weekly by fluorescence imaging with an Illumatool 9900 (Lightools Research). Tumors were harvested on days 30, 45, 60, and 70 after injection and processed for immunohistochemistry as described. Select mice were injected with 1 mg of MPA for 24 h before death.
Immunohistochemistry. Immunohistochemistry on paraffin sections of tumors was described (19) . For the current studies, samples were stained with a single-mouse mAb (CK5, CD44, CD24, PR) and visualized by using the Envision system (Dako) or dual stained by using the antibody combinations CK5/CD44, CK5/PR, and CD44/PR, where the second antibodies were rabbit mAbs. Secondary antibodies were anti-mouse and -rabbit Alexa Fluor 488 (green) and 555 (red)-conjugated, respectively. A Nikon E600 microscope was used for photography. Images were shot in black and white by using ImagePro software (Media Cybernetics) and merged in Adobe Photoshop 7.0.
